Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
QuintilesIMS
Baxter
McKesson
Cantor Fitzgerald
Covington

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 8,747,854

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,747,854
Title:Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
Abstract: The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNF.alpha. inhibitor, such as a human TNF.alpha. antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNF.alpha. inhibitor for treating hidradenitis suppurativa in a subject.
Inventor(s): Okun; Martin M. (Libertyville, IL), Harris; Thomas C. (Gurnee, IL)
Assignee: AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:13/153,131
Patent Claims:see list of patent claims

Details for Patent 8,747,854

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up AbbVie Biotechnology Ltd. (Hamilton, BM) 2036-04-30 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up AbbVie Biotechnology Ltd. (Hamilton, BM) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Citi
Cantor Fitzgerald
Teva
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.